2525 WEST END AVENUE, NASHVILLE,, TN
Reg. FD
Reports Company Update & Q2 2026 Financial Results
Announces Special Dividend of $1.50 Per Share
Closes Strategic Transaction with Apotex
Shareholder Approval for Strategic Transaction with Apotex Inc.
Reports Q1 2026 Financial Results & Company Update
Cumberland Pharmaceuticals Shareholders Approve Director Elections and Auditor
Announces Strategic Transaction to Integrate Commercial Business with Apotex
Q2
Q1
FY 2025
Q3
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Definitive Merger Proxy Statement
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
PREM14A
Submission Upload
Correspondence